Exploring the biological characteristics of bone marrow suppression induced by platinum-based chemotherapy based on multi-omics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600120513

Enrollment

Unknown

Registered

2026-03-16

Start date

2026-03-19

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor Patients

Interventions

Patients with solid tumors scheduled to receive platinum?based chemotherapy:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with pathologically confirmed solid tumors; (2) Unrelated Han Chinese population; (3) Aged 18-75 years, any gender; (4) Patients with solid tumors planned to receive platinum-based chemotherapy; (5) No chemotherapy received in the past six months; (6) Bone marrow function requirements before chemotherapy: White blood cell (WBC) count >= 4.0×10?/L, Absolute Neutrophil Count (ANC) >= 2.0×10?/L, Platelet count (PLT) >= 100×10?/L, Hemoglobin (HGB) >= 110 g/L; (7) Renal function requirement: Creatinine = 60 points, and expected survival > 3 months; (10) Willing to accept the treatment protocol of this study, sign the informed consent form, and have good compliance.

Exclusion criteria

Exclusion criteria: (1) Complicated with severe gastrointestinal diseases (such as intestinal perforation and infection, Crohn's disease, ulcerative colitis) or autoimmune diseases; (2) Severe cardio-cerebrovascular diseases (such as myocardial infarction, heart failure (NYHA Class III–IV)); (3) Diseases such as stroke, uncontrolled hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure >=110 mmHg), and hematological diseases; (4) History of drug/alcohol abuse; (5) Pregnancy or lactation; (6) Radiotherapy administered within 30 days prior to the start of the study, concurrently, or planned within 91 days; (7) Presence of acute or active chronic infections; (8) History of bone marrow or hematopoietic stem cell transplantation; (9) Investigator-assessed ineligibility for enrollment.

Design outcomes

Primary

Measure	Time frame
Time to the first occurrence of grade II or higher myelosuppression;Metabolomics and proteomics;	—

Countries

China

Contacts

Public ContactQinghua Yao

The Second Affiliated Hospital of Zhejiang Chinese Medical University

danfer1001@163.com+86 135 8889 9111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026